Orionis Biosciences Secures $55 Million Financing To Support Advancement Into Clinic

Oct 19, 2022•about 3 years ago

Amount Raised

$55 Million

WalthamTherapeuticsBiotechnologyHealth Care

Description

Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today announced it has completed a $55 million financing round and expanded its team, naming Robert Petit, Ph.D., as Senior Vice President, Early Clinical Development and Bihua Chen to the Orionis Board of Directors.

Company Information

Company

Orionis Biosciences

Location

Waltham, Massachusetts, United States

About

Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Orionis Biosciences Secures $55 Million Financing To Support Advancement Into Clinic

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information